Dr Paolo Gallipoli
Clinical Senior Lecturer
Haematology
Queen Mary University of London
Queen Mary University of London
Research
Acute myeloid leukaemia, Biology, Metabolism, Therapy
Interests
We use in vitro models to study the biology and therapy of acute myeloid leukaemia. We always strive to make our models more relevant. For example we have now developed coculture systems to grow leukaemia cells with several different stromal cells and are able to show differences in the leukaemia cell behaviour which are likely more reflective of what happens in vivoPublications
Publications of specific relevance to Predictive in vitro Models
2024
Sánchez-Lanzas R, Barclay J, Hardas A, Kalampalika F, Jiménez-Pompa A, Gallipoli P and Ganuza M (2024). A CADASIL NOTCH3 mutation leads to clonal hematopoiesis and expansion of Dnmt3a-R878H hematopoietic clones. Springer Nature Leukemia 1-13.
Othman J, Hwang A, Brodermann M, Abdallah I, McCloskey K, Gallipoli P, Clarke G, Dang R, Vidler J, Krishnamurthy P, Basheer F, Latif A-L, Palanicawandar R, Taylor T, Khan A, Campbell V, Hogan F, Kanellopoulos A, Fleming K, Collins A, Dalley C, Loke J, Marshall S, Taussig D, Munisamy S, Loizou E, Yassin H, Dennis M, Zhao R and Belsham E (2024). Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy. American Society of Hematology Blood Advances vol. 8, (21) 5590-5597.
Borek WE, Nobre L, Pedicona SF, Campbell AE, Christopher JA, Nawaz N, Perkins DN, Moreno-Cardoso P, Kelsall J, Ferguson HR, Patel B, Gallipoli P, Arruda A, Ambinder AJ, Thompson A, Williamson A, Ghiaur G, Minden MD, Gribben JG, Britton DJ, Cutillas PR and Dokal AD (2024). Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia. Elsevier EBioMedicine vol. 108,
Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, Rees D, Byrne J, Gallipoli P, Francis S, Copland M, Horne G, Raghavan M, Arnold C, Collins A, Cranfield T, Cunningham N, Danga A, Forsyth P, Frewin R, Garland P, Hannah G, Avenoso D, Hassan S, Huntly BJP, Husain J, Makkuni S, Rothwell K, Khorashad J and Apperley JF (2024). Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Springer Nature Leukemia vol. 38, (11) 2443-2455.
Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, Mehta P, Yassin H, Laurie J, Austin M, Gallipoli P, Taylor T, Dennis M, Elliot J, Clarke G, Dang R, Vidler J, Krishnamurthy P, Latif A-L, Kalkur P, Shahidianakbar M, Campbell V, Mannari D, Sutherland E, Wickramaratne T, Collins A, Zhao R, Mak H, Belsham E and Banerjee S (2024). Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Elsevier Blood Neoplasia vol. 1, (3)
Dembitz V, Lawson H, Burt R, Natani S, Philippe C, James SC, Atkinson S, Durko J, Wang LM, Campos J, Magee AMS, Woodley K, Austin MJ, Rio-Machin A, Casado P, Bewicke-Copley F, Rodriguez Blanco G, Pereira-Martins D, Oudejans L, Boet E, von Kriegsheim A, Schwaller J, Finch AJ, Patel B, Sarry J-E, Tamburini J, Schuringa JJ, Hazlehurst L, Copland III JA and Yuneva M (2024). Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation. Springer Nature Leukemia vol. 38, (11) 2395-2409.
Rodriguez Cutillas P, Borek WE, Christopher JA, Nobre LV, Campbell A, Kelsall J, Pedicona F, Nawaz N, Perkins DN, Cardoso PM, Arruda A, Ambinder AJ, Dutta S, Gallipoli P, Sill H, Ghiaur G, Minden MD, Williamson A, Gribben JG and Dokal AD (2024). Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML). American Society of Clinical Oncology (ASCO) Journal of Clinical Oncology vol. 42, (16_suppl) 6525-6525.
Robertson HF, Milojkovic D, Butt N, Byrne J, Claudiani S, Copland M, Gallipoli P, Innes AJ, Knight K, Mahdi AJ, Parker J, Virchis A and Apperley JF (2024). Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy. Wiley British Journal of Haematology vol. 205, (3) 947-955.
Lawson H, Holt-Martyn JP, Dembitz V, Kabayama Y, Wang LM, Bellani A, Atwal S, Saffoon N, Durko J, van de Lagemaat LN, De Pace AL, Tumber A, Corner T, Salah E, Arndt C, Brewitz L, Bowen M, Dubusse L, George D, Allen L, Guitart AV, Fung TK, So CWE, Schwaller J, Gallipoli P, O’Carroll D, Schofield CJ and Kranc KR (2024). The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia. Springer Nature Nature Cancer vol. 5, (6) 916-937.
Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin M, Latif A-L, Amer M, Chan WY, Crawley C, Crolla F, Cross J, Dang R, Elliot J, Fong CY, Galli S, Gallipoli P, Hogan F, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Loo S, Marshall S, Mehta P, Murthy V, Nagumantry S, Pillai S and Potter N (2024). Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. American Society of Hematology Blood vol. 143, (4) 336-341.
Dembitz V, Durko J, Campos J, James SC, Lawson H, Kranc KR and Gallipoli P (2024). Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient‐derived xenografts. Wiley HemaSphere vol. 8, (1)
2023
Milojkovic D, Blijlevens N, Kwong Y-L, Zaidi U, Castagnetti F, Gallipoli P, Miggiano MC, Westerweel PE, Chen M, Hernandez MCG, Kell WJ, Vachhani P, Agarwal N, Colasante A, Meka S, Smyth A, Ferreira G and Janssen JJWM (2023). Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP). American Society of Hematology Blood vol. 142, (Supplement 1)
Dokal A, Borek WE, Nobre L, Pedicona SF, Wrench B, Gallipoli P, Arruda A, Campbell AE, Nawaz N, Ferguson HR, Perkins DN, Moreno‐Cardoso P, Thompson A, Williamson AJK, Minden MD, Gribben JG, Britton DJ and Cutillas PR (2023). S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT‐POSITIVE ACUTE MYELOID LEUKAEMIA. Wiley HemaSphere vol. 7, (Suppl)
Philippe C, Mian S, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D, Morales V, Finch A, D’Alessandro A, Bianchi K, Wang J, Gallipoli P, Kordasti S, Kubasch AS, Cross M, Platzbecker U, Wiseman D, Bonnet D, Bernard D, Gribben J and Rouault-Pierre K (2023). O20 TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS. Elsevier Leukemia Research vol. 128,
Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Rattigan KM, Philippe C, Dembitz V, Magee AMS, Asby R, van de Lagemaat LN, Mapperley C, James SC, Prehn JHM, Tzelepis K, Rouault-Pierre K, Vassiliou GS, Kranc KR, Helgason GV, Huntly BJP and Gallipoli P (2023). Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death. Springer Nature Nature Communications vol. 14, (1)
Fernando F, Innes AJ, Claudiani S, Pryce A, Hayden C, Byrne J, Gallipoli P, Copland M, Apperley JF and Milojkovic D (2023). The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia. Springer Nature Bone Marrow Transplantation vol. 58, (7) 826-828.
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I, Heiblig M, Boet E, Sahal A, Saland E, Santos JC, Armengol M, Fernández-Serrano M, Farge T, Cognet G, Simonetta F, Pignon C, Graffeuil A, Mazzotti C, Avet-Loiseau H, Delos O, Bertrand-Michel J, Chedru A, Dembitz V, Gallipoli P, Anstee NS, Loo S and Wei AH (2023). C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia. American Association for Cancer Research (AACR) Cancer Discovery vol. 13, (7) 1720-1747.
Mian SA, Philippe C, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D, Morales V, Finch AJ, D’Alessandro A, Bianchi K, Wang J, Gallipoli P, Kordasti S, Kubasch AS, Cross M, Platzbecker U, Wiseman DH, Bonnet D, Bernard DG, Gribben JG and Rouault-Pierre K (2023). Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia. American Association for the Advancement of Science (AAAS) Science Translational Medicine vol. 15, (685) eabn5135-eabn5135.
2022
Dembitz V, Lawson H, Philippe C, Burt RJ, James S, Magee ASM, Woodley K, Durko J, Campos J, Austin MJ, Rio-Machin A, Izquierdo PC, Bewicke-Copley F, Blanco GR, Patel B, Hazlehurst L, Peck B, Finch A, Cutillas P, Fitzgibbon J, Yuneva M, Rouault-Pierre K, Copland J, Kranc K and Gallipoli P (2022). Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia. American Society of Hematology Blood vol. 140, (Supplement 1) 3058-3060.
Lawson H, Holt-Martyn J, Dembitz V, Durko J, Kabayama Y, Wang L, Van De Lagemaat L, Dubusse L, Alunno L, Guitart A, Schwaller J, Gallipoli P, O'Carroll D, Schofield C and Kranc K (2022). Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML. American Society of Hematology Blood vol. 140, (Supplement 1) 8731-8732.
Innes AJ, Hayden C, Orovboni V, Rees D, Claudiani S, Fernando F, Khan A, Byrne J, Gallipoli P, Francis S, Copland M, Horne G, Raghavan M, Arnold C, Collins A, Cranfield T, Cunningham N, Danga A, Forsyth P, Frewin R, Garland P, Hannah G, Hassan S, Huntly BJP, Husain J, Makkuni S, Rothwell K, Foroni L, Apperley JF and Milojkovic D (2022). Real-World Experience of Asciminib: Factors Associated with Response. American Society of Hematology Blood vol. 140, (Supplement 1) 6796-6797.
Othman J, Tiong IS, Mokretar K, Ivey A, Austin MJ, Latif A-L, Crawley C, Amer M, Crolla F, Cross JW, Dang R, Fong CY, Galli S, Gallipoli P, Hogan FL, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Marshall SR, Murthy V, Nagumantry SK, Pillai S, Potter N, Taylor T, Zhao R, Wei AH and Dillon R (2022). Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy. American Society of Hematology Blood vol. 140, (Supplement 1) 2033-2035.
Gallipoli P (2022). AML gets upSET when its dietary needs are unMet. American Society of Hematology Blood vol. 140, (19) 2003-2004.
Dawson MA, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass J, Kamdar M, Manteca M-VM, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A and Kremer BE (2022). A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. American Association for Cancer Research (AACR) Clinical Cancer Research vol. 29, (4) 711-722.
Innes A, Orovboni V, Claudiani S, Fernando F, Khan A, Byrne J, Gallipoli P, Copland M, Horne G, Arnold C, Collins A, Cunningham N, Danga A, Frewin R, Garland P, Hannah G, Hassan S, Makkuni S, Rothwell K, Foroni L, Hayden C, Apperley J and Milojkovic D (2022). P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE. Wiley HemaSphere vol. 6, 601-602.
Gallipoli P, Clark RE, Byrne J, Apperley JF, Milojkovic D, Foroni L, Goldman JM and O’Brien S (2022). The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia. Wiley British Journal of Haematology vol. 196, (6) e55-e57.
2021
Mian S, Philippe C, Maniati E, Bergot T, Piganeau M, Di Bella D, Morales V, Finch A, Bianchi K, Wang J, Gallipoli P, Platzbecker U, Wiseman DH, Bonnet D, Bernard D, Gribben J and Rouault-Pierre K (2021). Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia. American Society of Hematology Blood vol. 138, (Supplement 1)
Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Tzelepis K, Philippe C, Rattigan K, Asby R, Dembitz V, Magee ASM, Helgason G, Rouault-Pierre K, Vassiliou GS, Huntly BJP and Gallipoli P (2021). Mannose Metabolism Is a Metabolic Vulnerability Unveiled By Standard and Novel Therapies in Acute Myeloid Leukemia. American Society of Hematology Blood vol. 138, (Supplement 1)
Othman J, Afzal U, Amofa R, Austin MJ, Bashford A, Belsham E, Byrne J, Coats T, Dang R, Dennis M, Dhawan S, Elliot J, Francis S, Gallipoli P, Hodgson K, Kallmeyer C, Jain M, Katsomitrou V, Khan A, Khwaja A, Kolade S, Krishnamurthy P, Latif A, Laurie J, Lim M, Loke CT, Manson C, Marshall SR, Mobashwera B and Munisamy S (2021). Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service. American Society of Hematology Blood vol. 138, (Supplement 1)
Othman J, Amer M, Amofa R, Anderson L, Austin MJ, Bashford A, Belsham E, Boot J, Campbell VL, Coats T, Collins A, Crawley C, Crolla F, Cross JW, Dalley C, Dang R, Dennis M, Dhawan S, Elliott J, Galli S, Gallipoli P, Hodgson K, Jain M, Kalkur P, Katsomitrou V, Khan A, Khwaja A, Krishnamurthy P, Latif A and Laurie J (2021). Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service. American Society of Hematology Blood vol. 138, (Supplement 1)
Yun H, Narayan N, Vohra S, Giotopoulos G, Mupo A, Madrigal P, Sasca D, Lara-Astiaso D, Horton SJ, Agrawal-Singh S, Meduri E, Basheer F, Marando L, Gozdecka M, Dovey OM, Castillo-Venzor A, Wang X, Gallipoli P, Müller-Tidow C, Osborne CS, Vassiliou GS and Huntly BJP (2021). Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. Springer Nature Nature Genetics vol. 53, (10) 1443-1455.
Dembitz V and Gallipoli P (2021). The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia. Frontiers Frontiers in Oncology vol. 11,
Hughes CFM, Gallipoli P and Agarwal R (2021). Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome. Elsevier Pathology
2020
Forte D, García-Fernández M, Sánchez-Aguilera A, Stavropoulou V, Fielding C, Martín-Pérez D, López JA, Costa ASH, Tronci L, Nikitopoulou E, Barber M, Gallipoli P, Marando L, de Castillejo CLF, Tzankov A, Dietmann S, Cavo M, Catani L, Curti A, Vázquez J, Frezza C, Huntly BJ, Schwaller J and Méndez-Ferrer S (2020). Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. Elsevier Cell Metabolism vol. 32, (5) 829-843.e9.
Castelli R, Bergamaschini L, Teatini T, Cilumbriello L, Schiavon R, Gallipoli P and Deliliers GL (2020). Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study. Elsevier Clinical Lymphoma Myeloma & Leukemia vol. 20, (8) e461-e467.
Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf TH, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark RE, Milojkovic D, Helgason GV, Foroni L, Nicolini FE, Holyoake TL and Copland M (2020). A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Springer Nature Leukemia vol. 34, (7) 1775-1786.
2019
Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills R, Russell N, Osborne CS, Papaemmanuil E, Göttgens B, Campbell P and Huntly BJP (2019). Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. American Society of Hematology Blood vol. 134, (24) 2195-2208.
Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Khorashad JS, Foroni L, Milojkovic D and Apperley JF (2019). Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). American Society of Hematology Blood vol. 134, (Supplement_1)
Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS and Huntly BJP (2019). Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. Rockefeller University Press Journal of Experimental Medicine vol. 216, (4) 966-981.
Gallipoli P and Huntly BJP (2019). Histone modifiers are oxygen sensors. American Association for the Advancement of Science (AAAS) Science vol. 363, (6432) 1148-1149.
Gallipoli P and Huntly BJP (2019). Prognostic Models Turn the Heat(IT)up on FLT3ITD-Mutated AML. American Association for Cancer Research (AACR) Clinical Cancer Research vol. 25, (2) 460-462.
2018
Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu W-H, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C and Bradley A (2018). SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Springer Nature Nature Communications vol. 9, (1)
Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL and Bergamaschini L (2018). Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Springer Nature Journal of Thrombosis and Thrombolysis vol. 47, (1) 155-156.
Gallipoli P (2018). JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients. Elsevier Leukemia Research vol. 75, 71-72.
Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C and Huntly BJP (2018). Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. American Society of Hematology Blood vol. 131, (15) 1639-1653.
2017
Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL and Bergamaschini L (2017). High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. Springer Nature Journal of Thrombosis and Thrombolysis vol. 45, (1) 106-113.
Gallipoli P and Huntly BJP (2017). Novel epigenetic therapies in hematological malignancies: Current status and beyond. Elsevier Seminars in Cancer Biology vol. 51, 198-210.
2016
Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG, Vetrie D, Holyoake TL and Michie AM (2016). CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood
Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS and Yusa K (2016). A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Elsevier Cell Reports vol. 17, (4) 1193-1205.
Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P, Cruz M, Dunn K, Jorgensen HG, Cassels JE, Hamilton A, Crossan A, Sinclair A, Holyoake TL and Vetrie D (2016). Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition. American Association for Cancer Research Cancer Discovery vol. 6, (11) 1248-1257.
Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA and Castelli R (2016). Laboratory and clinical risk assessment to treat myelodysplatic syndromes. De Gruyter Clinical Chemistry and Laboratory Medicine vol. 54, (9) 1411-1426.
2015
Castelli R, Pantaleo G, Gallipoli P, Gidaro A, Arquati M, Wu MA and Deliliers GL (2015). Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. Wolters Kluwer Anti-Cancer Drugs vol. 26, (10) 1078-1082.
Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan W-I, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ and Huntly BJP (2015). A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. Rockefeller University Press Journal of Experimental Medicine vol. 212, (10) 1551-1569.
Hopcroft LEM, Calderhead B, Gallipoli P, Holyoake TL and Girolami MA (2015). Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia. Systems Genetics Cambridge University Press (CUP)
Gallipoli P, Giotopoulos G and Huntly BJP (2015). Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. SAGE Publications Therapeutic Advances in Hematology vol. 6, (3) 103-119.
Giotopoulos G, Chan W-I, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA and Huntly BJP (2015). The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Springer Nature Oncogene vol. 35, (3) 279-289.
2014
Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton AD, Jørgensen HG, Bhatia R and Holyoake TL (2014). JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. American Society of Hematology Blood vol. 124, (9) 1492-1501.
Colombo R, Gallipoli P and Castelli R (2014). Thrombosis and Hemostatic Abnormalities in Hematological Malignancies. Elsevier Clinical Lymphoma Myeloma & Leukemia vol. 14, (6) 441-450.
Castelli R, Deliliers GL, Colombo R, Moreo G, Gallipoli P and Pantaleo G (2014). Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Springer Nature Annals of Hematology vol. 93, (9) 1523-1529.
2013
Giotopoulos G, Chan W-I, Ruau D, Gallipoli P, Fowler A, Göttgens B, Van Deursen J, Cole P and Huntly B (2013). The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML). American Society of Hematology Blood vol. 122, (21)
Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG and Holyoake TL (2013). Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. American Society of Hematology Blood vol. 122, (19) 3335-3339.
Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M and Holyoake TL (2013). Safety and efficacy of pulsed imatinib with or without G‐CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow‐up. Wiley British Journal of Haematology vol. 163, (5) 674-676.
Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL and Jiang X (2013). Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex. Oxford University Press (OUP) Journal of the National Cancer Institute vol. 105, (6) 405-423.
McIlwaine L, Parker A, Sandilands G, Gallipoli P and Leach M (2013). Neutrophil‐specific granule deficiency. Wiley British Journal of Haematology vol. 160, (6) 735-735.
2012
Shah M, Gallipoli P, Lyons J, Holyoake T and Jørgensen H (2012). Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Elsevier Blood Cells Molecules and Diseases vol. 48, (3) 199-201.
2011
Gallipoli P, Abraham SA and Holyoake TL (2011). Hurdles Toward a Cure for CML: The CML Stem Cell. Elsevier Hematology/Oncology Clinics of North America vol. 25, (5) 951-966.
Gallipoli P, Shepherd P, Irvine D, Drummond M and Holyoake T (2011). Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. Wiley British Journal of Haematology vol. 155, (1) 128-130.
2010
DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H, Saw KM, Chan M, Newmarch K, Zhou L, Turhan AG, Arlinghaus RB, Eaves AC, Eaves CJ, Holyoake TL and Jiang X (2010). Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells. American Society of Hematology Blood vol. 116, (21)
2009
Hamilton A, Gallipoli P, Nicholson E and Holyoake TL (2009). Targeted therapy in haematological malignancies. Wiley The Journal of Pathology vol. 220, (4) 404-418.
Gallipoli P, Clark A and Leach M (2009). The evolving management of a rare lymphoproliferative disorder–T‐cell prolymphocytic leukemia. Wiley American Journal of Hematology vol. 84, (11) 750-753.
Fyfe AJ and Gallipoli P (2009). Multiple splenic calcifications. Wiley British Journal of Haematology vol. 144, (6) 808-808.
Gallipoli P, Drummond M and Leach M (2009). Hemophagocytosis and relapsed peripheral T‐cell lymphoma. Wiley European Journal Of Haematology vol. 82, (3) 246-246.
Gallipoli P and Drummond M (2009). Pseudotumour cerebri as a manageable side effect of prolonged all‐trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia. Wiley European Journal Of Haematology vol. 82, (3) 242-243.
2008
Gallipoli P, Tang A and Leach M (2008). Cortical blindness due to sagittal sinus thrombosis in acute lymphoblastic leukaemia. Wiley British Journal of Haematology vol. 145, (3) 270-270.
2007
Gallipoli P and Leach M (2007). Gingival infiltration in acute monoblastic leukaemia. Springer Nature British Dental Journal vol. 203, (9) 507-509.
2005
Finelli C, Gallipoli P, Celentano E, Cacace G, Saldalamacchia G, De Caprio C, Contaldo F and Pasanisi F (2005). Assessment of physical activity in an outpatient obesity clinic in southern Italy: Results from a standardized questionnaire. Elsevier Nutrition Metabolism and Cardiovascular Diseases vol. 16, (3) 168-173.
2002
Gallipoli P (2002). Medical education: Britain versus Italy. BMJ The BMJ vol. 324, (Suppl S2)
Gallipoli P (2002). Glasgow: a very interesting place. BMJ The BMJ vol. 324, (Suppl S2)
1992
Clark JA, Deutch AY, Gallipoli PZ and Amara SG (1992). Functional expression and CNS distribution of a β-alanine-sensitive neuronal GABA transporter. Elsevier Neuron vol. 9, (2) 337-348.
Grants
Optimising therapies targeting fatty acid desaturation in AML
Paolo Gallipoli
£94,540 EHA European Hematology Association (01-10-2024 - 30-09-2026)
Paolo Gallipoli
£94,540 EHA European Hematology Association (01-10-2024 - 30-09-2026)
DISSECTING THE ROLE OF MANNOSE METABOLISM IN LEUKEMIA AND NORMAL STEM CELL FUNCTION
Paolo Gallipoli
£320,237 Barts and the London Charity (12-06-2023 - 11-06-2026)
Paolo Gallipoli
£320,237 Barts and the London Charity (12-06-2023 - 11-06-2026)
Identification and characterisation of metabolic pathways as determinants of drug resistance in acute myeloid leukaemia
£1,412,196 CR-UK Cancer Research UK (01-10-2019 - 30-06-2026)
£1,412,196 CR-UK Cancer Research UK (01-10-2019 - 30-06-2026)